Acute urticaria in the infant
© 2020 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd..
Urticaria is a mast cell-driven disease presenting with wheals, angioedema, or both. Acute urticaria (AU) lasts < 6 weeks. AU is a not common condition in newborns and infants since they are showing an immune system functionally insufficient. In newborns and infants, AU is typically generalized and featured by large, annular, or geographic plaques, often slightly raised. The clinical features of the disease depend on the peculiar structure of neonatal and infant skin. A careful morphological examination of the lesions is essential to differentiate AU from other skin eruptions that may have overlapping features and to treat it adequately. The second-generation antihistamines are the first-line treatment of AU; however, only antihistamines with proven efficacy and safety should be used in newborns and infants. Corticosteroids may be added in severe cases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 Suppl 26 |
|---|---|
| Enthalten in: |
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology - 31 Suppl 26(2020) vom: 03. Nov., Seite 49-51 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Minasi, Domenico [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute urticaria |
|---|
| Anmerkungen: |
Date Completed 18.08.2021 Date Revised 18.08.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/pai.13350 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318031434 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318031434 | ||
| 003 | DE-627 | ||
| 005 | 20231225164515.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/pai.13350 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1060.xml |
| 035 | |a (DE-627)NLM318031434 | ||
| 035 | |a (NLM)33236443 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Minasi, Domenico |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acute urticaria in the infant |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.08.2021 | ||
| 500 | |a Date Revised 18.08.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. | ||
| 520 | |a Urticaria is a mast cell-driven disease presenting with wheals, angioedema, or both. Acute urticaria (AU) lasts < 6 weeks. AU is a not common condition in newborns and infants since they are showing an immune system functionally insufficient. In newborns and infants, AU is typically generalized and featured by large, annular, or geographic plaques, often slightly raised. The clinical features of the disease depend on the peculiar structure of neonatal and infant skin. A careful morphological examination of the lesions is essential to differentiate AU from other skin eruptions that may have overlapping features and to treat it adequately. The second-generation antihistamines are the first-line treatment of AU; however, only antihistamines with proven efficacy and safety should be used in newborns and infants. Corticosteroids may be added in severe cases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute urticaria | |
| 650 | 4 | |a angioedema | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a differential diagnosis | |
| 650 | 4 | |a infant | |
| 650 | 4 | |a newborn | |
| 650 | 7 | |a Histamine Antagonists |2 NLM | |
| 650 | 7 | |a Histamine H1 Antagonists, Non-Sedating |2 NLM | |
| 700 | 1 | |a Manti, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Chiera, Fernanda |e verfasserin |4 aut | |
| 700 | 1 | |a Licari, Amelia |e verfasserin |4 aut | |
| 700 | 1 | |a Marseglia, Gian Luigi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology |d 1994 |g 31 Suppl 26(2020) vom: 03. Nov., Seite 49-51 |w (DE-627)NLM075107252 |x 1399-3038 |7 nnns |
| 773 | 1 | 8 | |g volume:31 Suppl 26 |g year:2020 |g day:03 |g month:11 |g pages:49-51 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/pai.13350 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 Suppl 26 |j 2020 |b 03 |c 11 |h 49-51 | ||